roferon-a 6million units/0.5ml solution for injection pre-filled syringes
roche products ltd - interferon alfa-2a - solution for injection - 12mega unit/1ml
roferon-a 3million units/0.5ml solution for injection pre-filled syringes
roche products ltd - interferon alfa-2a - solution for injection - 6mega unit/1ml
roferon-a 4.5million units/0.5ml solution for injection pre-filled syringes
roche products ltd - interferon alfa-2a - solution for injection - 9mega unit/1ml
guna-inf alpha- interferon alfa-2a solution/ drops
guna spa - interferon alfa-2a (unii: 47rrr83sk7) (interferon alfa-2a - unii:47rrr83sk7) - recurrent viral infections recurrent viral infections
alferon- interferon alfa-n3 injection
aim immunotech inc - interferon alfa-n3 (unii: 47bpr3v3mp) (interferon alfa-n3 - unii:47bpr3v3mp) - interferon alfa-n3 5000000 [arb'u] in 1 ml
alpheon
biopartners gmbh - recombinant human interferon alfa-2a - hepatitis c, chronic - immunostimulants, - adult patients with histologically proven chronic hepatitis c who are positive for hepatitis c virus (hcv) antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.the efficacy of interferon alfa-2a in the treatment of hepatitis c is enhanced when combined with ribavirin. alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.
viraferonpeg
merck sharp dohme ltd - peginterferon alfa-2b - hepatitis c, chronic - immunostimulants, - adults (tritherapy)viraferonpeg in combination with ribavirin and boceprevir (tritherapy) is indicated for the treatment of chronic-hepatitis-c (chc) genotype-1 infection in adult patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy.please refer to the ribavirin and boceprevir summaries of product characteristics (smpcs) when viraferonpeg is to be used in combination with these medicines.adults (bitherapy and monotherapy)viraferonpeg is indicated for the treatment of adult patients (18 years of age and older) with chc who are positive for hepatitis-c-virus rna (hcv-rna), including patients with compensated cirrhosis and / or co-infected with clinically stable hiv.viraferonpeg in combination with ribavirin (bitherapy) is indicated for the treatment of chc infection in adult patients who are previously untreated including patients with clinically stable hiv co-infection and in adult patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated) and ribavirin combination therapy or interferon alpha monotherapy.interferon monotherapy, including viraferonpeg, is indicated mainly in case of intolerance or contraindication to ribavirin.please refer to the ribavirin smpc when viraferonpeg is to be used in combination with ribavirin.paediatric population (bitherapy)viraferonpeg is indicated in a combination regimen with ribavirin for the treatment of children three years of age and older and adolescents, who have chronic hepatitis c, previously untreated, without liver decompensation, and who are positive for hcv-rna.when deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. the decision to treat should be made on a case-by-case basis.please refer to the ribavirin smpc for capsules or oral solution when viraferonpeg is to be used in combination with ribavirin.
interferon alfa-2b 1million units/ml eye drops preservative free
special order - interferon alfa-2b - eye drops - 1mega unit/1ml
intron a solution
merck canada inc - interferon alfa-2b - solution - 6000000unit - interferon alfa-2b 6000000unit - interferons
intron a solution
merck canada inc - interferon alfa-2b - solution - 10000000unit - interferon alfa-2b 10000000unit - interferons